Company

Company

Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Arsenal Bio

Main focus: Next-generation autologous T cell therapies

Company stage: Commercial

Diseases (gene editing): Cancer

Genome editing tool: CRISPR

Funding stage: Private

Location: South San Francisco, CA, USA

Website: https://www.arsenalbio.com/

Gene editing partnerships: Bristol Myers Squibb

Arsenal Bio develops multiple proprietary technology platforms, CellFoundry™, PrimeR™ and CARchitecture™ which together with the CRISPR technology form the foundation for its next-generation therapies. While the company has yet to disclose its lead programmes, it has announced a collaboration with Bristol Myers Squibb (BMS) where the two companies will discover and develop T cell therapies for the treatment of solid tumours.

Your Latest CMN News

CMN Weekly (19 April 2024) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

A Secondary Checkpoint Refines CRISPR Precision

New findings highlight a secondary conformational checkpoint in CRISPR-Cas9 that significantly enhances its accuracy in gene editing.

Cancer's Weak Point Is Its Metabolism, CRISPR...

American researchers have developed a novel CRISPR-based platform to identify and characterise essential nutrient transporters that support cancer...

Next-Generation CRISPR Screening Libraries Without...

Sponsored content

Founded in 2018, Vivlion is a spin-out of Goethe University Frankfurt. Its mission is to provide innovative gene-editing reagents and screening...

CMN Weekly (12 April 2024) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

Scientists use CRISPR to develop new detection...

Scientists in China describe a sensitive and selective CRISPR-Cas12-based assay for the detection of a protein that is implicated in obesity and...

Company: Arsenal Bio

Search CRISPR Medicine